Found 25 matching trials
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer PHASE2 This is an open-label, multicenter international trial in men and women wit...
Show More Status
Active Not Recruiting
Location
Sainte Catherine - Institut du Cancer Avignon Provence
Learn More & Join Trial
A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib N/A The aim of this study was to assess the effectiveness, safety, and tolerabi...
Show More Learn More & Join Trial
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer PHASE3 The purpose of this open-label, multicenter, phase IIIb, single-arm study i...
Show More Location
Central Alabama Research
Learn More & Join Trial
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. PHASE2 This was a randomized, double-blind, placebo-controlled study conducted in ...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France N/A This study is a national, multicenter, prospective, non-interventional stud...
Show More Status
Active Not Recruiting
Location
Novartis Investigative Site
Learn More & Join Trial
First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer PHASE2 This phase II study focuses on women with rapidly progressive hormone recep...
Show More Location
Jiangsu Provincial People's Hospital
Learn More & Join Trial
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence N/A This non-interventional observational study evaluates the real-world effect...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC PHASE3 In this clinical trial, the Sponsor plans to investigate whether patients w...
Show More Location
Universitaetsklinikum Mannheim GmbH Frauenklinik
Learn More & Join Trial
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer PHASE3 A phase III, multicenter, randomized, open-label trial to evaluate the effi...
Show More Status
Active Not Recruiting
Location
University of Alabama at Birmingham-Kirklin Clinic
Learn More & Join Trial
A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients N/A The aim of this study was to assess real-world treatment patterns and toler...
Show More Learn More & Join Trial